Azenta Life Sciences and Frenova, a division of Fresenius Medical Care and a leader in renal precision medicine, have announced a strategic partnership to advance genomic research in nephrology. The collaboration will support Frenova’s MyReason® genomics research program, which aims to deepen understanding of cardio-kidney-metabolic (CKM) diseases and drive innovation in precision medicine.

The partnership is expected to significantly enhance data generation and genomic sequencing efforts that support research into genetic mechanisms behind kidney disease, helping shape the future of personalized treatment strategies.

MyReason®: A Landmark in CKM Research
Frenova’s MyReason® program is a groundbreaking initiative that already includes over 35,000 participants, with plans to expand to 50,000 over the next two years. Participants provide biospecimens used to study genomic, phenotypic, and clinical data. The data powers the Nephronomics Atlas a key resource supporting genomic exploration of CKM diseases.

The research aims to uncover novel therapeutic targets, disease subtypes, and genetic safety variants using advanced AI and machine learning models trained on this extensive dataset. Frenova and its partner Nephronomics are at the forefront of transforming CKM care through targeted therapeutic discovery.

Azenta’s Role in the Partnership
Azenta will play a vital role by delivering high-quality genomic sequencing via GENEWIZ and managing long-term biospecimen storage through its global biorepository network. With a strong track record in multiomics analysis and sample management, Azenta is positioned to support the complexity and scale of the MyReason® program.

Leadership Perspectives
Ginger Zhou, President of GENEWIZ, commented:

“We are excited to collaborate with Frenova and Nephronomics and support the MyReason research program. This partnership aligns with our mission to empower the scientific community with advanced genomic solutions.”

Jan Walter, President of Frenova, emphasized the significance of the project:

“This broad genome sequencing initiative symbolizes a vital milestone in our journey to form the most reliable genotype-phenotype database for CKM patients. We are excited to partner with Nephronomics to expand the Nephronomics Atlas and unlock insights that could transform patient care.”

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

James Sietstra, Founder of Nephronomics, added:

“The expertise in nephrology and Frenova’s MyReason initiative, merged with Azenta’s innovative genomic sequencing and sample management solutions, shows significant cornerstones of the Nephronomics Atlas. This partnership will help us advance scientific understanding and introduce new diagnostics and therapies for CKM conditions.”

Driving Forward Precision Medicine
The collaboration between Azenta, Frenova, and Nephronomics represents a significant leap forward in genomic-driven precision medicine. By integrating powerful genomic tools with clinical insights, the partnership seeks to accelerate discovery and deliver new hope for patients battling CKM diseases worldwide.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com